SEMA3A and breast cancer: Wallerius et al. reported that BC cell-derived SEMA3A worked through its receptor neuropilin 1 to suppress the proliferation of M2 TAMs in the Br-TME and that SEMA3A expression levels were correlated with the expression levels of genes characteristic of M1 TAMs, CD8+ T cells, and natural killer (NK) cells [135].